Specifics of ovarian cancer in patients with BRCA mutations: PARP Inhibitor Treatment in Ovarian and Breast Cancer

Česká verzia

Authors: Jana Halámková ^1,2; Katarína Petráková ¹; Jiří Tomášek ¹; Igor Kiss ¹
Authors place of work: Klinika komplexní onkologické péče LF MU a Masarykův onkologický ústav Brno, přednosta prof. MUDr. Rostislav Vyzula, CSc. ¹; Ústav lékařské etiky LF MU, Brno, vedoucí ústavu doc. Mgr. Josef Kuře, Dr. phil. ²
Published in the journal: Prakt Gyn 2014; 18(1): 54-59
Category: Oncogynecology: Review Article

Summary

Relationship BRCA germline mutations to the incidence of ovarian cancer is well known. The lifetime risk of development ovarian cancer is among BRCA1 gene mutation carriers 60 % and of BRCA2 gene mutation carriers around 10–20 %. The genes BRCA1 and BRCA2 belong to group of reparation genes, which participates in the repair of the DNA strand breaks by homologous recombination. Mutation in these cases leads to failure of DNA repair. Ovarian tumors in patients with BRCA mutations are relatively uniform behavior, characterized by higher response rates to platinum-based chemotherapy in the first as well as the other lines of treatment, longer survival, and usually high-grade serous carcinoma histology. In patients with ovarian or breast cancer, due to particularity of mutations in the BRCA genes 1 and 2, new molecules especially inhibitors of poly (ADP- ribose) polymerase (PARP), gets to forefront of the treatment. Inhibition of PARP activity in tumor cells with BRCA mutations leads to the suppression of the ability of DNA repair and improves the effect of cytotoxic treatment, but PARP inhibitors are also effective in monotherapy.

Key words:
BRCA – poly(ADP-ribose) polymerase inhibitors – iniparib – ovarian cancer – niraparib – olaparib – PARP – rucaparib – veliparib

Zdroje

1. Ústav zdravotnických informací a statistiky ČR. Dostupné z WWW <http://www.uzis.cz/katalog/zdravotnicka-statistika/novotvary>.

2. Jemal A, Siegel R, Ward E et al. Cancer statistics 2009. CA Cancer J Clin 2009; 59(4): 225–249.

3. Modesitt SC, Jazaeri AA. Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Expert Opin Pharmacother 2007; 8(14): 2293–2305.

4. Chovanec J. Karcinom ovaria. Postgrad med 2012; 9: 71–77.

5. Plevová P, Novotný J, Petráková K et al. Syndrom hereditárního karcinomu prsu a ovarií. In: Foretová L, Petráková K. Dispenzarizace dědičných nádorových syndromů. Klin Onkol 2009; 22(Suppl): 8–11.

6. Rubin SC, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335(19): 1413–1416.

7. Risch HA, McLaughlin JR, Cole DE et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006; 98(23): 1694–1706.

8. Jacobi CE, van Ierland Y, van Asperen CJ et al. Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort. Genet Med 2007; 9(3): 173–179.

9. Pal T, Permuth-Wey J, Betts JA et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104(12): 2807–2816.

10. Integrated genomic analyses of ovarian carcinoma. Cancer Genome Atlas Research Network. Nature 2011; 474(7353): 609–615.

11. Tassone P, Tagliaferri P, Perricelli A et al. BRCA1 expression modulates chemosensitivity of BRCA 1-defective HCC1937 human breast cancer cells. Br J Cancer 2003; 88(8): 1285–1291.

12. Lafarge S, Sylvain V, Ferrara M et al. Inhibition of BRCA 1 leads to increased chemoresistance to microtubule-interferins agents, an effect that involves the JNK pathway. Oncogene 2001; 20(45): 6597–6606.

13. Turner N, Tuttl A, Ashwort A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4(10): 814–819.

14. Brown LA, Irving J, Parker R et al. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 2006; 100(2): 264–270.

15. Hughes-Davies L, Huntsman D, Ruas M et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003; 115(5): 523–535.

16. Cousineau I, Belmaaza A. EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases. Mol Genet Genomics 2011; 285(4): 325–340.

17. D'Andrea AD. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle 2003; 2(4): 290–292.

18. Taniguchi T, Tischkowitz M, Ameziane N et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003; 9(5): 568–754.

19. Vencken PM, Kriege M, Hoogwerf D et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 2011; 22(6): 1346–1352.

20. Cass I, Baldwin RL, Varkey T et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003; 97(9): 2187–2195.

21. Chetrit A, Hirsh-Yechezkel G, Ben-David Y et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008; 26(1): 20–25.

22. Pal T, Permuth-Wey J, Kapoor R et al. Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer 2007; 6(1): 113–119.

23. Gourley C, Michie CO, Roxburgh P et al. Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J Clin Oncol 2010; 28(15): 2505–2511.

24. Jóhannsson OT, Ranstam J, Borg A et al. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998; 16(2): 397–404.

25. Tan DS, Rothermundt C, Thomas K et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26(34): 5530–5536.

26. Lorusso D, Cirillo F, Mancini M et al. The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience. Oncology 2013; 85(2): 122–127.

27. Hyman DM, Zhou Q, Iasonos A et al. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 2012; 118(15): 3703–3709.

28. McLaughlin JR, Rosen B, Moody J et al. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst 2013; 105(2): 141–148.

29. Tong WM, Cortes U, Wang ZQ. Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. Biochim Biophys Acta 2001; 1552(1): 27–37.

30. Helleday T, Petermann E, Lundin C et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8(3): 193–204.

31. Virág L, Szabó C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002; 54(3): 375–429.

32. d'Adda di Fagagna F, Hande MP, Tong WM et al. Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability. Nat Genet 1999; 23(1): 76–80.

33. Weil MK, Chen AP. PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer 2011; 35(1): 7–50.

34. Tesařová P. Novinky v cílené biologické léčbě karcinomu prsu. Postgrad med 2011; 6: 609–615.

35. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2- deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434(7035): 913–917.

36. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434(7035): 917–921.

37. Evers B, Drost R, Schut E et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14(12): 3916–3925.

38. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376(9737): 245–251.

39. Ledermann J, Harter P, Gourley Ch et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366(15): 1382–1392.

40. Ledermann J, Harter P, Gourley Ch et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). ASCO Annual meeting 2013. J Clin Oncol 2013; 31(Suppl): Abstr 5505.

41. Sandhu SK, Schelman WR, Wilding G et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 2013; 14(9): 882–892.

42. de Bono JS, Mina LA, Gonzalez M. First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. ASCO Annual meeting 2013. J Clin Oncol 2013; 31(Suppl): Abstr 2580.

43. Rigakos G, Razis E. BRCAness: finding the Achilles heel in ovarian cancer. Oncologist 2012; 17(7): 956–962.